Changes in Patient Functioning and Disability: Results from Two Phase 3 Double-Blind Placebo-Controlled Clinical Trials Evaluating Galcanezumab for Episodic Migraine Prevention (EVOLVE-1 and EVOLVE-2)

被引：0
|
作者：
Ford, J. [1 ]
Ayer, D. [1 ]
Zhang, Q. [2 ]
Carter, J. [2 ]
Skljarevski, V [2 ]
Aurora, S. [2 ]
机构：
[1] Eli Lilly & Co, Indianapolis, IN USA
[2] Eli Lilly & Co, Indianapolis, IN 46285 USA
来源：
HEADACHE | 2018年 / 58卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
PS37
引用
收藏
页码：171 / 172
页数：2
相关论文
共 50 条
  • [31] Galcanezumab in episodic migraine: subgroup analyses of efficacy by high versus low frequency of migraine headaches in phase 3 studies (EVOLVE-1 & EVOLVE-2) (vol 20, 75, 2019)
    Silberstein, Stephen D.
    Stauffer, Virginia L.
    Day, Katie A.
    Lipsius, Sarah
    Wilson, Maria-Carmen
    JOURNAL OF HEADACHE AND PAIN, 2019, 20 (01):
  • [32] Galcanezumab in episodic migraine: the phase 3, randomized, double-blind, placebo-controlled PERSIST study
    Bo Hu
    Gang Li
    Xiaohong Li
    Shan Wu
    Tingmin Yu
    Xiang Li
    Hongru Zhao
    Zhihua Jia
    Junpeng Zhuang
    Shengyuan Yu
    The Journal of Headache and Pain, 2022, 23
  • [33] Galcanezumab in episodic migraine: the phase 3, randomized, double-blind, placebo-controlled PERSIST study
    Hu, Bo
    Li, Gang
    Li, Xiaohong
    Wu, Shan
    Yu, Tingmin
    Li, Xiang
    Zhao, Hongru
    Jia, Zhihua
    Zhuang, Junpeng
    Yu, Shengyuan
    JOURNAL OF HEADACHE AND PAIN, 2022, 23 (01):
  • [34] Hepatic safety of galcanezumab in patients with migraine: Results of three Phase 2 double-blind placebo-controlled trials
    Regev, Arie
    Camporeale, Angelo
    Skljarevski, Vladimir
    Wang, Shufang
    Carter, Jeff
    NEUROLOGY, 2017, 88
  • [35] Hepatic Safety of Galcanezumab in Patients with Migraine: Results of Three Phase 2 Double-blind Placebo-controlled Trials
    Regev, A.
    Camporeale, A.
    Skljarevski, V
    Wang, S.
    Carter, J.
    HEADACHE, 2017, 57 : 182 - 182
  • [36] Hepatic safety of galcanezumab in patients with migraine: Results of three Phase 2 double-blind placebo-controlled trials
    Regev, Arie
    Camporeale, Angelo
    Skljarevski, Vladimir
    Wang, Shufang
    Carter, Jeff
    NEUROLOGY, 2017, 88
  • [37] Measures of Functioning in Patients With Episodic Migraine: Findings From a Double-Blind, Randomized, Placebo-Controlled Phase 2b Trial With Galcanezumab
    Ayer, David W.
    Skljarevski, Vladimir
    Ford, Janet H.
    Nyhuis, Allen W.
    Lipton, Richard B.
    Aurora, Sheena K.
    HEADACHE, 2018, 58 (08): : 1225 - 1235
  • [38] A phase 3 placebo-controlled study of galcanezumab in patients with episodic migraine: Results from the 3-month double-blind treatment phase of the PERSIST study
    Yu, S.
    Hu, B.
    Li, G.
    Jia, Z.
    Chowdhury, D.
    Zhuang, J.
    Qian, C.
    HEADACHE, 2022, 62 : 130 - 131
  • [39] Reducing the impact of migraine on functioning: Results from the STRIVE trial, a phase 3, randomised, double-blind, placebo-controlled study of erenumab in patients with episodic migraine
    Buse, Dawn C.
    Lipton, Richard B.
    Mikol, Daniel D.
    Thach, Andrew V.
    Desai, Pooja
    Picard, Hernan
    Kubo, Yumi
    Hareendran, Asha
    Kawata, Ariane K.
    JOURNAL OF HEADACHE AND PAIN, 2017, 18
  • [40] Results of a randomized, double-blind, placebo-controlled, phase 2 study to evaluate the efficacy and safety of AMG 334 for the prevention of episodic migraine
    Lenz, R.
    Silberstein, S.
    Dodick, D.
    Reuter, U.
    Ashina, M.
    Saper, J.
    Cady, R.
    Chon, Y.
    Dietrich, J.
    Sun, H.
    CEPHALALGIA, 2015, 35 : 5 - 5
12345